Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells | Wu et al. Journal of Hematology Oncology 2010 3 43 http content 3 1 43 JOURNAL OF HEMATOLOGY ONCOLOGY RESEARCH Open Access Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells Qiong Wu1 Shu-Kui Qin2 Feng-Meng Teng3 Chang-Jie Chen3 Rui Wang1 Abstract Background Hepatocellular carcinoma HCC still is a big burden for China. In recent years the third-generation platinum compounds have been proposed as potential active agents for HCC. However more experimental and clinical data are warranted to support the proposal. In the present study the effect of lobaplatin was assessed in five HCC cell lines and the underlying molecular mechanisms in terms of cell cycle kinetics were explored. Methods Cytotoxicity of lobaplatin to human HCC cell lines was examined using MTT cell proliferation assay. Cell cycle distribution was determined by flow cytometry. Expression of cell cycle-regulated genes was examined at both the mRNA RT-PCR and protein Western blot levels. The phosphorylation status of cyclin-dependent kinases CDKs and retinoblastoma Rb protein was also examined using Western blot analysis. Results Lobaplatin inhibited proliferation of human HCC cells in a dose-dependent manner. For the most sensitive SMMC-7721 cells lobaplatin arrested cell cycle progression in G1 and G2 M phases time-dependently which might be associated with the down-regulation of cyclin B CDK1 CDC25C phosphorylated CDK1 pCDK1 pCDK4 Rb E2F and pRb and the up-regulation of p53 p21 and p27. Conclusion Cytotoxicity of lobaplatin in human HCC cells might be due to its ability to arrest cell cycle progression which would contribute to the potential use of lobaplatin for the management of HCC. Background Hepatocellular carcinoma HCC is one of the most common cancers with poor prognosis. In China alone more than 401 000 new patients were diagnosed with HCC and more than 371 000 patients died of this disease in 2008 1 . The poor outcome of HCC is mainly due to it .
